Abstract Eicosapentaenoic acid (EPA) has antiarrhythmic effects. The J-wave on an electrocardiogram is associated with a high incidence of ventricular tachycardia/ fibrillation (VT/VF). We evaluated relationships between EPA and J-waves, and their involvement in the occurrence of VT/VF in acute myocardial infarction (AMI). Two hundred consecutive patients undergoing successful percutaneous coronary intervention within 12 h after AMI onset were enrolled. Serum EPA level and J-waves at admission were evaluated. The patients were divided into two groups according to the optimal cutoff value (2.94) of serum EPA level (% of total fatty acids): LOW (\2.94, 61 ± 11 years, n = 103) and HIGH groups (C2.94, 70 ± 13 years, n = 81). J-waves were observed more frequently in the LOW (36/103, 35 %) than in HIGH group (16/81, 20 %) (P = 0.020). The 30-day incidence of VT/VF including those occurring before admission was higher in the LOW (19.5 %) than in HIGH group (6.2 %) (P = 0.009). The patients with J-waves showed a higher incidence of VT/VF (23.1 %) than those without J-waves (9.9 %) (P = 0.019). Kaplan-Meier analysis showed that the highest incidence of VT/VF was observed in the LOW with J-wave group (27.8 %), followed by the LOW without J-wave (15.0 %), HIGH with J-wave (12.5 %), and HIGH without J-wave (4.6 %) (P = 0.013). Cox proportional hazard analysis revealed that Killip grade and low serum EPA level or presence of J-waves were significantly associated with the incidence of VT/VF. Low serum EPA level is a risk for incidence of VT/VF in the acute phase of myocardial infarction. Involvement of the J-wave and its possible link with EPA in the pathogenesis of ischemia-induced VT/VF are suggested.
Introduction
Sudden cardiac death (SCD) is one of the most common causes of death, and the majority of SCD is directly caused by ischemia-related acute ventricular arrhythmias such as ventricular tachycardia and ventricular fibrillation (VT/ VF). The development of an effective strategy for preventing ischemia-induced VT/VF in the early phase of acute myocardial infarction (AMI) is urgently required.
The consumption of fish oil containing large amounts of n-3 polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA, C20:5) and docosahexaenoic acid (DHA, C22:5), was shown to reduce the risk of cardiovascular events and death [1] . The GISSI-Prevenzione trial found a 45 % reduction in sudden death in patients consuming n-3 PUFAs [2] . Furthermore, the JELIS trial showed that EPA combined with statin significantly reduced major coronary events in hypercholesterolemic patients with established coronary artery disease [3, 4] . n-3 PUFAs were also shown to have antiarrhythmic effects in animal and human studies [5] [6] [7] . However, the detailed mechanisms by which n-3 PUFAs exert their beneficial effects on SCD and ischemia-induced VT/VF have not been fully elucidated.
The J-wave is an electrocardiogram (ECG) waveform defined by a ''notching'' or ''slurring'' at the terminal point of the QRS complex. Whereas previously the J-wave had been regarded as a benign finding in healthy individuals, recent studies have shown that it is a finding suggestive of the development of idiopathic VF such as a coved type ST elevation seen in Brugada syndrome [8] . Furthermore, several reports showed that the J-wave is seen commonly in patients with acute ischemia complicated by VT/VF [9, 10] , suggesting an important causative role of the J-wave in not only idiopathic but also ischemia-induced VT/VF.
It is well known that the adenosine triphosphate (ATP)-sensitive potassium channel (K ATP channel) is activated by ischemia, and the appearance of the J-wave is affected by K ATP -channel activity [11, 12] . Recently, EPA has been shown to inhibit K ATP -channel activation in the swine model of myocardial ischemia [13] . Thus there may be some associations among acute ischemia-induced VT/VF, low serum EPA level, and the presence of the J-wave, but there have been no reports investigating these associations in clinical cases. The purpose of this study was to examine whether the acute-phase incidence of VT/VF is related to the serum EPA level and the appearance of the J-wave in patients with AMI. We further discuss a possible link between the serum EPA level and the J-wave in the pathogenesis of VT/VF via ischemia-induced activation of K ATP channels.
Patients and methods

Study patients
This study enrolled 200 consecutive patients with AMI who were transferred to Hirosaki University Hospital within 12 h after symptom onset and underwent successful emergent percutaneous coronary intervention (PCI) from August 2010 to March 2012. Those showing pacemaker rhythm (n = 4) and left or right bundle branch block (n = 12) were excluded. After admission, all patients underwent 12-lead ECG recording and venous blood sampling to measure serum PUFA concentrations and blood chemistry. The diagnosis of AMI was made by chest pain consistent with ongoing myocardial ischemia, ischemic ECG changes, and increases in the serum creatine kinase MB isoform (CK-MB) level C2 times the upper limit of normal and cardiac troponin T level C0.1 ng/ml. PCI was done mostly with the use of a bare-metal stent. In all patients, clinical events during the first 30 days after the onset were carefully observed. The study protocol was approved by the Ethical Committee on Human Research of our institution.
ECG evaluation
The standard 12-lead ECG recorded at admission was used for the analyses of the baseline RR interval, QRS duration, J-wave, and QT and QTc intervals. As reported previously [8, 14] , the J-wave was defined as a notching (a positive J-deflection inscribed on the S-wave) or slurring (a smooth transition from the QRS segment to the ST segment), and was considered to be present when its amplitude was [0.1 mV above the isoelectric line either in at least two consecutive inferior leads (II, III, aVF), left precordial leads (V4-V6), or high lateral leads (I, aVL) (Fig. 1) . The isoelectric line was defined as a level of the preceding TP segment [8, 14] . The amplitude of the J-wave was measured in the fivefold magnified ECG tracing, and the maximal amplitude was evaluated. VT/VF was detected from documentation of continuous ECG monitoring in the ambulance or in the ward. VT encompassed only sustained VT, which was defined as VT lasting[30 s and at least 150 beats/min, and/or complicated by hemodynamic compromise requiring cardioversion.
Measurement of plasma fatty acids
Levels of plasma fatty acids at the time of admission were measured by the external laboratory (SRL, Tokyo, Japan). In brief, plasma lipids were extracted by Folch's procedure, after which fatty acids (tricosanoic acid, C23:0, as the internal standard) were methylated with boron trifluoride and methanol. The methylated fatty acids were then analyzed using a capillary gas chromatograph (GC-2010; Shimadzu, Kyoto, Japan). The serum EPA level (%) was expressed as a percentage of the total fatty acids [3, 15] .
Statistical analysis
Continuous variables were listed as mean ± standard deviation (SD) and were compared using Student's t test. Categorical variables were compared using the v 2 test. The optimal cutoff point for serum EPA level was determined by receiver-operating characteristic (ROC) curves for distinguishing patients with VT/VF. Analyses of cumulative incidence of VT/VF were performed according to the Kaplan-Meier method, and the curves were compared using the log-rank test. Univariate Cox regression analysis and multivariate Cox proportional hazard analysis were performed to identify hazard ratios (HR) and 95 % confidence intervals (CI). Probabilities of\5 % were considered statistically significant. All analyses were performed using the statistical software package SPSS version 18.0 (SPSS, Chicago, IL, USA).
Results
Patients' profiles
The patients were divided into two groups based on the optimal cutoff value for serum EPA level (2.94, sensitivity = 80 % and specificity = 48 %): the LOW group with the level \2.94 (n = 103) and the HIGH group with the level C2.94 (n = 81). The baseline characteristics of the two groups of patients are summarized in Table 1 . The mean age in the LOW group was significantly lower than that in the HIGH group (61 ± 11 vs 70 ± 13 years, P \ 0.001). Total fatty acids were significantly higher in the LOW group than in the HIGH group. As expected, a significantly lower level of serum EPA was found in the LOW group than in the HIGH group. By contrast, the serum arachidonic acid (AA) level was significantly higher in the LOW group than in the HIGH group. This resulted in a significantly lower EPA/AA ratio in the LOW group than in the HIGH group. Regarding the plasma lipid levels, total The RR interval, QRS duration, and QT and QTc intervals on the baseline ECG were all similar between the two groups (Table 2) . Importantly, the J-wave was observed in 52 (28 %) patients, and the incidence was more frequent in the LOW group than in the HIGH group (36/103, 35 % vs 16/81, 20 %; P = 0.02). This was further confirmed by the finding that the serum EPA level was significantly lower in the 52 patients with the J-wave than in the other 132 without the J-wave (2.47 ± 1.47 vs 3.04 ± 1.66, P = 0.03).
A detailed analysis of the J-wave is summarized in Table 3 . Except for the incidence, there were no significant differences in the mean amplitude and morphology (notched or slurred type) of the J-wave between the two groups. The J-wave was observed most often in the inferior leads on the ECG (34 of 52, 65 %).
Incidence of ventricular arrhythmias during the acute phase VT/VF occurred in 25 cases (VT 3 cases, VF 18 cases, VT and VF 4 cases), and more frequently in the LOW group than in the HIGH group, within 30 days after the onset of AMI (P = 0.009 by log-rank test) (Fig. 2a) . The first episode of VT/VF mostly occurred before admission in both groups (13 of 19 in the LOW group and 4 of 6 in the HIGH group). When the incidence of VT/VF was compared between the patient groups with and without the J-wave, it was higher in the group with the J-wave than in the group without the J-wave (P = 0.019 by log-rank test) (Fig. 2b) . These Kaplan-Meier analyses suggest that the low serum EPA level and the presence of J-wave are both associated with the increased incidence of VT/VF.
To further investigate the relationships, the patients were divided into four groups according to the serum EPA level and the presence of J-wave: LOW with the J-wave (LOW-JW (?), n = 36), LOW without the J-wave (LOW-JW (-), n = 67), HIGH with the J-wave (HIGH-JW (?), n = 16), and HIGH without the J-wave (HIGH-JW (-), n = 65). Kaplan-Meier analysis showed that the highest incidence of VT/VF was observed in the LOW with J-wave group (27.8 %), followed by LOW without J-wave (15.0 %), HIGH with J-wave (12.5 %) and HIGH without J-wave (4.6 %) groups (P = 0.013).
In addition, we performed Kaplan-Meier analysis using the absolute EPA value (optimal cutoff value, 85.7 lg/ml) as well as the serum EPA level expressed as a percentage of the total fatty acids, and found similar Kaplan-Meier curves (P = 0.014 by log-rank test).
Incidence of ventricular arrhythmias evaluated by serum EPA/AA ratio Serum EPA/AA ratio is known as a predictive marker for coronary death and AMI [4] . Therefore, we performed the Kaplan-Meier analysis for the other four groups, which were divided according to the optimal cutoff value for the serum EPA/AA ratio (0.47, sensitivity = 72 %, specificity = 53 %) and appearance of the J-waves. As shown in Fig. 3 , we found similar Kaplan-Meier curves (P = 0.015) for both serum EPA level and serum EPA/AA ratio.
Predictors for ventricular arrhythmias
The results of univariate and multivariate Cox proportional hazard analyses to elucidate the predictors for the development of VT/VF are shown in Table 4 . Univariate 
Discussion
The present study showed that a low serum EPA level is a risk factor for VT/VF during the acute phase of myocardial infarction (MI), and the J-wave, more frequently found in patients with a low level of serum EPA, is associated with the increased incidence of VT/VF as estimated by KaplanMeier analysis. These findings indicate a significant importance of low serum EPA level and the J-wave in the pathogenesis of VT/VF during the acute phase of MI, and further suggest a possible mechanistic link between low serum EPA level and presence of the J-wave in the patients presenting with VT/VF in the acute phase of MI.
Beneficial effect of n-3 PUFAs on the occurrence of VT/VF and its possible mechanism n-3 PUFAs have been shown to exert beneficial effects on long-term cardiovascular events after AMI [15] . However, few studies have examined their favorable effects on the lethal arrhythmic events during the acute phase of MI. Aarsetøy et al. [16] showed that the plasma levels of n-3 PUFAs were significantly lower in patients having a VF event during the acute phase MI than in those without such an event. This supports our finding that VT/VF occurred more frequently in the LOW group than in the HIGH group within 30 days after the onset of AMI. We further showed a significant importance of the low serum EPA level as an independent predictor for the occurrence of VT/VF by multivariate analysis. Although the higher concentration of total fatty acid and triglycerides in the LOW group may affect the incidence of ventricular arrhythmia, the results of three Kaplan-Meier analyses using serum EPA level expressed as a percentage of the total fatty acids, the absolute value of EPA, and the EPA/ AA ratio support an important role of low serum EPA levels in the incidence of ventricular arrhythmia in patients with AMI. The underlying mechanism by which a high level of serum EPA exerts a protective effect on the occurrence of VT/VF during the acute phase of MI is of great interest. n-3 PUFAs exert their antiarrhythmic effects possibly because of modulation of ion channels, particularly voltage-gated sodium, potassium, and L-type calcium channels [17] . Experimental animal studies indicated that a dietary supplementation of n-3 PUFAs significantly reduced the incidence and severity of ventricular arrhythmias occurring after coronary artery occlusion in a canine model by inhibiting the rapid accumulation of intracellular calcium following ischemia [5] . In a human electrophysiologic study, the infused or dietary n-3 PUFA decreased the inducibility of VT in patients with implantable cardioverter-defibrillators at risk of SCD [6] . Although these animal and clinical studies clearly described the antiarrhythmic effects of n-3 PUFAs, their precise mechanism in the setting of acute ischemia has not been fully elucidated.
During myocardial ischemia, intracellular ATP concentration decreases and subsequently the K ATP channel is activated, thereby leading to the shortening of the duration of action potential and heterogeneous ventricular repolarization [18] . This process causes transmural differences in the early phase of cardiac action potential and eventually induces phase-2 reentry and VT [19] . In a swine model of myocardial ischemia, EPA was shown to reduce the risk of VF and mortality, possibly by attenuating the monophasic action potential [13] . At the cellular level, EPA was found to inhibit mRNA transcription and protein expression of Kir6.2, a major component of sarcolemmal K ATP channels [13] . This experimental observation strongly suggests that EPA exerts an antiarrhythmic effect, partly via inhibition of ischemia-induced activation of K ATP channels. HR hazard ratio, CI confidence interval. Other abbreviations are as shown in Table 1 Inhibition of J-wave appearance by n-3 PUFAs
Another important issue to be discussed in this study is how EPA influences the appearance of J-wave on the ECG. The J-wave was originally regarded as a benign finding in healthy individuals. However, recent reports showed that the presence of the J-waves is associated with an increased risk of VT/VF during acute myocardial ischemia [9, 10, 20] , and is an independent predictor for the occurrence of VF in the very early phase of AMI [21] . We showed that the J-wave was observed more frequently in the LOW group than in the HIGH group, and the incidence of VT/VF was also higher in the LOW group than in the HIGH group, supporting the existence of detrimental effects of the J-wave during the acute phase of MI. Furthermore, our findings suggest a possible interaction between the low serum EPA level and J-wave for the occurrence of VT/VF. Activation of K ATP channels and/or their difference in distribution between the epicardial and endocardial myocardium partly contribute to the manifestation of the J-wave [22, 23] . Taken together, this may logically allow us to propose a possible mechanism whereby EPA inhibits ischemia-induced activation of K ATP channels and thereby reduces K ATP channel-induced manifestation of the J-wave, which in turn leads to the decrease in the incidence of VT/ VF during the acute phase of MI (Fig. 4) . This proposal, and our finding that almost all patients in this study population were not treated with EPA before admission, seems to warrant immediate EPA treatment after AMI to prevent VT/VF events in the acute phase of MI. Further experimental and large clinical studies are required to justify our speculation.
Appearance of J-wave and its morphology
As VT/VF is most commonly observed in the acute phase of MI, we analyzed the ECG and the J-wave at admission, a time as close as possible to the onset of AMI. In other clinical studies evaluating the J-wave, the ECG was recorded 5 or 7 days after admission [24, 25] . However, PCI may have been undertaken by that time, and the possibility that PCI influenced the ECG waveform cannot be completely excluded. Furthermore, the appearance of the J-wave and its morphology also change with time, and the J-wave may disappear immediately in some cases [10] . Our protocol to evaluate the ECG and the J-wave on admission concurs with that used in other studies [24, 25] . The frequency of J-waves in our study (28 %) and the lead location on the ECG where the J-wave was observed were both similar to those in other studies [20, 21, 24] . Our study further showed that more than half of the J-waves were a slurred type, whereas in the other studies the majority of the J-wave were a notched type [17, 25] . This difference in J-wave morphology could be explained by the different timing of the observation and the different genetic background of the patients.
Limitations
There are some limitations to this study. First, it is unknown whether the patients had the J-wave prior to the onset of AMI. Accordingly, although we found the J-wave to be associated with the occurrence of VT/VF, we could not elucidate the behavior of the J-wave prior to the onset of VT/VF. Second, the number of patients was perhaps too small to determine a suitable cutoff value for the serum EPA level and to adequately examine its relationship with the incidence of VT/VF. Further large-scale and prospective clinical studies are required.
Conclusions
Our study provides evidence that a low level of serum EPA is a risk factor for the occurrence of VT/VF in the acute phase of MI and that the J-wave is involved in the pathogenesis of VT/VF. More notably, a possible mechanistic link between the low serum EPA level and the appearance of the J-wave, presumably through K ATP -channel activation, is suggested to be a novel pathogenesis of ischemia- Fig. 4 Proposed mechanism by which eicosapentaenoic acid (EPA) exerts an antiarrhythmic effect on ischemia-induced ventricular tachycardia/fibrillation (VT/VF). EPA inhibits ischemia-induced activation of K ATP channels and thereby reduces K ATP channelinduced manifestation of J-waves. This process may lead to a decrease in the incidence of VT/VF during the acute phase of myocardial infarction. ATP adenosine triphosphate induced VT/VF. A supplementary EPA treatment might be recommended to prevent VT/VF in AMI, especially in patients with a low serum EPA level and the J-wave.
